Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Gastroenterology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
 

Colon cancer; rectal cancer Clinical Trials

A listing of Colon cancer; rectal cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (179) clinical trials

Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers

Aspirin in patients with dukes C or high risk dukes B colorectal cancer can improve survival in this patient population over placebo control. Eligible patients will be randomized to treatment arms, using the following stratification factors: - Study Centre - Tumour Type - Type of adjuvant chemotherapy received(exposed/not exposed to ...

Phase

Study Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography to Detect Hypoxia in Locally Advanced (T3-T4 and./or N1)Primary Rectal Cancer Patients

Hypoxia is a characteristic feature of malignant solid tumors associated with poor prognosis and resistance to chemotherapy and radiation. It has also been shown (6) that the presence of hypoxia may reduce long-term survival post surgery. Hypoxia renders tumor cells up to three times more resistant to ionizing radiation than ...

Phase

MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer

OBJECTIVES: Primary - To determine the alteration of tumor blood flow using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in patients with advanced or metastatic colorectal cancer after 2 courses of combination chemotherapy comprising oxaliplatin, fluorouracil, and leucovorin (FOLFOX) and bevacizumab at 5 mg/kg vs 10 mg/kg or FOLFOX alone. Secondary ...

Phase

Treatment Outcomes of Hepatic Metastasis After FOLFOX-4 Therapy

In 2000, de Gramont et al. and Giacchetti et al. reported that combination chemotherapy including modulated infusional 5-Fu plus irinotecan and oxaliplatin could achieve a response rate of approximately 50% and a median survival of in excess of 20 months. These encouraging results implied that chemotherapy is likely to play ...

Phase

Personalized Screening Plans to Increase Colorectal Cancer Screening in Healthy Participants

OBJECTIVES: - To compare the impact of tailored intervention vs standard intervention vs usual care on patient utilization of colorectal cancer (CRC) screening. - To compare the impact of these interventions on CRC screening preference. - To compare the impact of these interventions on patient perceptions about CRC screening. OUTLINE: ...

Phase

General Surgical Outcomes Quality Improvement Database (UH-SOCRATES)

Since the Institute of Medicine report, titled "To Err is Human", there has been an increasing trend to evaluate outcomes in healthcare. While optimal outcomes in delivery of healthcare are something that hospitals and their medical, nursing and administrative staff have always tried to achieve, this has often been attempted ...

Phase N/A

Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer

OBJECTIVES: Primary - Analyze various biological factors that can be used as markers to predict response to treatment and correlate with the signaling pathway of EGFR. Secondary - Establish a tissue bank to store information about the response to treatment and survival. OUTLINE: Patients undergo endoscopy, 11 biopsies of tumor ...

Phase N/A

Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

OBJECTIVES: Primary - Evaluate the objective response (RECIST criteria) at 6 months associated with FOLFIRI and bevacizumab therapy. - Evaluate the tolerability (NCI CTC v. 2.0 criteria) of this treatment. Secondary - Evaluate progression-free survival and overall survival. - Determine the time to treatment failure. - Evaluate the quality of ...

Phase

Phase 3 Study of Surgery Combined With Neoadjuvant Chemotherapy(XELOX) in Colorectal Cancer With Resectable Liver Metastasis

Liver metastasis is the most important prognostic factor of colorectal cancer. Reasonable multidisciplinary therapy might improve the prognosis of patients with liver metastasis. Surgery has been the first choice under such situation. Recently, neoadjuvant chemotherapy has also shown its value in unresectable liver metastasis, for it can increase the chance ...

Phase